Liver cancer trial halted: drug combo vs. standard therapy
Disease control
Terminated
This study aimed to see if a combination of two drugs (regorafenib and pembrolizumab) worked better than standard treatments (TACE or TARE) for people with intermediate-stage liver cancer. The trial was planned for about 496 participants but was stopped early, so only limited dat…
Phase: PHASE3 • Sponsor: Translational Research in Oncology • Aim: Disease control
Last updated May 15, 2026 11:54 UTC